A novel genetically engineered oilseed: A controlled assessment of two bioactive substances intended for commercialization

一种新型基因工程油籽:对两种用于商业化的生物活性物质的受控评估

基本信息

  • 批准号:
    491882-2015
  • 负责人:
  • 金额:
    $ 1.82万
  • 依托单位:
  • 依托单位国家:
    加拿大
  • 项目类别:
    Engage Grants Program
  • 财政年份:
    2015
  • 资助国家:
    加拿大
  • 起止时间:
    2015-01-01 至 2016-12-31
  • 项目状态:
    已结题

项目摘要

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are essential fatty acids that are produced only by aquatic plants (these compounds are not found in terrestrial plants) and are critical to our neurological and cardiovascular health. However, we (and indeed all other vertebrates) do not make these compounds very efficiently, so they must, in large part, be obtained from the diet (e.g. by eating fish and/or fish oil pills). Sourcing EPA and DHA from wild fish is quickly becoming both environmentally- and economically-unsustainable. As a solution to this problem, oilseed crops (such as canola and camelina) have been genetically engineered (GE) to produce EPA and DHA at levels similar to fish oil, which can then be used by several different industries (nutraceuticals, aquaculture) to replace fish oil. Linnaeus Plant Sciences (LPS) is keen to grow and commercialize GE camelina in Canada, and would be the first to do so on a commercial scale globally. However, commercialization will require testing to demonstrate that introducing GE camelina to the Canadian agroecosystem will not unduly benefit crop pests. We propose to conduct the initial research required to begin the commercialization process, understand the effects, and transfer this key knowledge to LPS. To begin the assessment process, we plan to investigate the effect of EPA and DHA on the biology of crop pests.
二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)是必需脂肪酸,仅由水生植物产生(这些化合物在陆生植物中没有发现),对我们的神经和心血管健康至关重要。然而,我们(实际上所有其他脊椎动物)不能非常有效地制造这些化合物,因此它们必须在很大程度上从饮食中获得(例如通过吃鱼和/或鱼油丸)。从野生鱼类中获取EPA和DHA在环境和经济上都变得不可持续。作为解决这个问题的一种方法,油籽作物(如油菜和亚麻荠)经过基因工程(GE),以产生与鱼油相似水平的EPA和DHA,然后可以被几个不同的行业(营养品,水产养殖)用来取代鱼油。Linnaeus Plant Sciences(LPS)热衷于在加拿大种植和商业化转基因亚麻荠,并将成为全球第一个在商业规模上这样做的公司。然而,商业化将需要进行测试,以证明将转基因亚麻荠引入加拿大农业生态系统不会对作物害虫产生过度的好处。我们建议进行开始商业化过程所需的初步研究,了解影响,并将这些关键知识转移到LPS。为了开始评估过程,我们计划调查EPA和DHA对作物害虫生物学的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Arts, Michael其他文献

Arts, Michael的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Arts, Michael', 18)}}的其他基金

Biochemical Changes in Aquatic Organisms in a Warming World
变暖世界中水生生物的生化变化
  • 批准号:
    RGPIN-2014-04537
  • 财政年份:
    2019
  • 资助金额:
    $ 1.82万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical Changes in Aquatic Organisms in a Warming World
变暖世界中水生生物的生化变化
  • 批准号:
    RGPIN-2014-04537
  • 财政年份:
    2017
  • 资助金额:
    $ 1.82万
  • 项目类别:
    Discovery Grants Program - Individual
Omega-3 fatty acids in diatom-dominated biofilms in the Fraser River Estuary: Quantifying nutrient sources for migratory bird populations
弗雷泽河口硅藻为主的生物膜中的 Omega-3 脂肪酸:量化候鸟种群的营养源
  • 批准号:
    499579-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 1.82万
  • 项目类别:
    Engage Grants Program
Biochemical Changes in Aquatic Organisms in a Warming World
变暖世界中水生生物的生化变化
  • 批准号:
    RGPIN-2014-04537
  • 财政年份:
    2016
  • 资助金额:
    $ 1.82万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical Changes in Aquatic Organisms in a Warming World
变暖世界中水生生物的生化变化
  • 批准号:
    RGPIN-2014-04537
  • 财政年份:
    2015
  • 资助金额:
    $ 1.82万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical Changes in Aquatic Organisms in a Warming World
变暖世界中水生生物的生化变化
  • 批准号:
    RGPIN-2014-04537
  • 财政年份:
    2014
  • 资助金额:
    $ 1.82万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical tracers in freshwater ecosystems
淡水生态系统中的生化示踪剂
  • 批准号:
    227463-2011
  • 财政年份:
    2011
  • 资助金额:
    $ 1.82万
  • 项目类别:
    Discovery Grants Program - Individual

相似海外基金

Functional characterization of schizophrenia rare variants using genetically engineered human iPSCs
使用基因工程人类 iPSC 进行精神分裂症罕见变异的功能表征
  • 批准号:
    10554598
  • 财政年份:
    2023
  • 资助金额:
    $ 1.82万
  • 项目类别:
Orthogonal CRISPR GEMMs
正交 CRISPR GEMM
  • 批准号:
    10639698
  • 财政年份:
    2023
  • 资助金额:
    $ 1.82万
  • 项目类别:
Immunomodulatory and behavioral effects of CAR T regulatory cell therapy for Alzheimer's Disease”.
CAR T 调节细胞疗法对阿尔茨海默病的免疫调节和行为影响。
  • 批准号:
    10633721
  • 财政年份:
    2023
  • 资助金额:
    $ 1.82万
  • 项目类别:
Advancing On-Slide and Optical Biopsy Tools to Detect High-Risk Oral Premalignancy
先进的载玻片和光学活检工具来检测高风险口腔癌前病变
  • 批准号:
    10768888
  • 财政年份:
    2023
  • 资助金额:
    $ 1.82万
  • 项目类别:
On circuit mechanisms of reward behaviors after early-life adversity
论早年逆境后奖赏行为的循环机制
  • 批准号:
    10735759
  • 财政年份:
    2023
  • 资助金额:
    $ 1.82万
  • 项目类别:
Engineering Exosome for Pancreatic Cancer Targeting Therapies
用于胰腺癌靶向治疗的外泌体工程
  • 批准号:
    10803020
  • 财政年份:
    2023
  • 资助金额:
    $ 1.82万
  • 项目类别:
Acetate and Endothelial Pathobiology
醋酸盐和内皮病理学
  • 批准号:
    10736268
  • 财政年份:
    2023
  • 资助金额:
    $ 1.82万
  • 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
  • 批准号:
    10442874
  • 财政年份:
    2023
  • 资助金额:
    $ 1.82万
  • 项目类别:
UBR5's mechanisms of action in tumorigenesis and immunoregulation
UBR5在肿瘤发生和免疫调节中的作用机制
  • 批准号:
    10659844
  • 财政年份:
    2023
  • 资助金额:
    $ 1.82万
  • 项目类别:
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 1.82万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了